Surgical Shipping Verified by LostJobs.AI: October 25, 2026

Medtronic Hugo RAS

Made by Medtronic

Medtronic Hugo RAS

Photo: Medtronic

Starting price $1,350,000 · Medtronic does not publish a price. Capital-cost figures of roughly $1.2M to $1.5M circulate in secondary coverage, but we could not trace them to a primary source, so we leave the price field empty. ↗
Key specs
imaging
KARL STORZ 3D HD
analytics
Touch Surgery video AI
fda pending
510(k)s for general surgery (incl. hernia) and gynecology submitted June 3, 2026; no clearance reported yet
architecture
modular: 4 independent arm carts plus open console and tower
console design
open (surgeon sits up; sees and talks to the OR team)
energy platform
Valleylab FT10
wristed instruments
9
fda first indication
urologic surgery (Dec 2025): prostate, kidney, bladder procedures
global countries available
35
global procedures completed
tens of thousands; Medtronic expects to pass 50,000 by fiscal year-end (April 2027)

Who's exposed

Jobs in the threat radius

  • surgical first assistant (specific subtasks the wristed instruments absorb)
  • operating room circulating nurse (reduced per-procedure headcount as robot workflows standardize)
  • surgical technologist (instrument-handling roles where modular arm carts cut prep and turnover labor)

Deployment status

[Re-verified 2026-10-25: status unchanged, two facts added.] FDA cleared Hugo in December 2025 for urologic procedures, the first major Western competitor cleared against Intuitive's da Vinci in more than 20 years. The first U.S. commercial case was on February 17, 2026 at Cleveland Clinic (prostatectomy, Dr. Jihad Kaouk). On June 3, 2026 Medtronic submitted 510(k)s to add general surgery, including hernia repair, and gynecology; we found no clearance reported as of this check. On the September 1 Q1 FY27 call, CEO Geoff Martha said Medtronic expects Hugo to pass 50,000 completed procedures by fiscal year-end and procedure growth of more than twice the market rate, and the CFO said Hugo's contribution to Medical Surgical growth is increasing. Medtronic did not disclose a U.S. installed base, system count or Hugo revenue. Outside the U.S. Hugo is in use in more than 35 countries after nearly five years of commercial experience.

When this hits the labor market

Surgical robotics doesn't displace surgeons. It changes which procedures are done robotically, where, and at what staffing ratio. Hugo's near-term effect is competitive: a second credible platform in the U.S. gives hospitals a second quote on a capital purchase and accelerates mid-sized hospitals adding a robot. That shifts OR time from open and standard laparoscopic technique and trims demand at the margin for surgical first assistants, scrub techs and circulating nurses on cases that migrate. Three to five years for that margin-shift to compound across U.S. urology; longer for gynecology and general surgery, where the 510(k)s are still pending.

The first real competitor to da Vinci in 20 years

For more than two decades the U.S. robotic surgery market had one product on it, Intuitive Surgical’s da Vinci. The FDA’s December 2025 clearance of Hugo for urologic procedures ended that. A second platform changes the economics of every hospital RAS purchase from here on, whether or not Hugo outperforms da Vinci on day one.

The first U.S. case was on February 17, 2026 at Cleveland Clinic, a robotic prostatectomy by Dr. Jihad Kaouk. Outside the U.S. Hugo has been in use for nearly five years across more than 35 countries.

What changed since we cataloged it

Two things, both from Medtronic itself. On June 3 the company filed 510(k)s to take Hugo into general surgery, hernia repair included, and gynecology. Nothing says they have been cleared. And on the September 1 earnings call Medtronic said it expects Hugo to pass 50,000 completed procedures by the end of its fiscal year in April 2027, with procedure growth at more than twice the market’s rate.

What Medtronic did not say is as useful. No U.S. installed base, no number of systems placed, no Hugo revenue. The 50,000 figure is global and a forecast. A reader should hold it as the company’s ambition, not a count of American operating rooms.

What the platform is

Hugo is four independent arm carts that wheel into the room, an open surgeon console, and a tower with KARL STORZ 3D HD imaging and the Valleylab FT10 energy platform. Hospitals can share arms across ORs. The console is open: the surgeon sits up and talks to the team, unlike da Vinci’s immersed eyepiece. Nine wristed instruments cover the urology indication.

Why we care for LostJobs

The line we hold on da Vinci applies here. A surgical robot does not take the surgeon’s job. A second credible platform pushes down the price of getting a robot into an OR, and more robotic cases follow. The exposed roles are surgical first assistants whose tasks wristed instruments absorb, and scrub techs and circulating nurses whose per-case headcount compresses as robotic workflows standardize. The pending general surgery and gynecology filings are the part to watch: if they clear, Hugo reaches the procedure categories where staffing effects are largest.

Is this robot coming for your job?

Press releases speak in averages — LostJobs talks about your role. Find out which parts of your job hold up and which don't. Free.

Talk to LostJobs about my future